Your browser doesn't support javascript.
loading
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Lin, Luping; Sabnis, Amit J; Chan, Elton; Olivas, Victor; Cade, Lindsay; Pazarentzos, Evangelos; Asthana, Saurabh; Neel, Dana; Yan, Jenny Jiacheng; Lu, Xinyuan; Pham, Luu; Wang, Mingxue M; Karachaliou, Niki; Cao, Maria Gonzalez; Manzano, Jose Luis; Ramirez, Jose Luis; Torres, Jose Miguel Sanchez; Buttitta, Fiamma; Rudin, Charles M; Collisson, Eric A; Algazi, Alain; Robinson, Eric; Osman, Iman; Muñoz-Couselo, Eva; Cortes, Javier; Frederick, Dennie T; Cooper, Zachary A; McMahon, Martin; Marchetti, Antonio; Rosell, Rafael; Flaherty, Keith T; Wargo, Jennifer A; Bivona, Trever G.
Afiliação
  • Lin L; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Sabnis AJ; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA. [3] Department of Pediatrics, Division of Pediatric Hematology and Oncolog
  • Chan E; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Olivas V; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Cade L; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Pazarentzos E; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Asthana S; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Neel D; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Yan JJ; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Lu X; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Pham L; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Wang MM; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Karachaliou N; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Cao MG; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Manzano JL; Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Ramirez JL; Translational Oncology Laboratory, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Fundació Institut Recerca Germans Trias i Pujol (IGTP), Barcelona, Spain.
  • Torres JM; Medical Oncology Service, Hospital Universitario de La Princesa, Madrid, Spain.
  • Buttitta F; Center for Predictive Molecular Medicine, University Foundation, Chieti-Pescara, Chieti, Italy.
  • Rudin CM; 1] Molecular Chemistry and Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [2] Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Collisson EA; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Algazi A; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Robinson E; Ronald O. Perelman Department of Dermatology, Medicine and Urology, New York University Cancer Institute, New York, New York, USA.
  • Osman I; Ronald O. Perelman Department of Dermatology, Medicine and Urology, New York University Cancer Institute, New York, New York, USA.
  • Muñoz-Couselo E; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Cortes J; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Frederick DT; 1] Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Massachusetts General Hospital Comprehensive Cancer Center, Boston, Massachusetts, USA.
  • Cooper ZA; 1] Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA. [2] Department of Genomic Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
  • McMahon M; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Marchetti A; Center for Predictive Molecular Medicine, University Foundation, Chieti-Pescara, Chieti, Italy.
  • Rosell R; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Flaherty KT; 1] Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Massachusetts General Hospital Comprehensive Cancer Center, Boston, Massachusetts, USA.
  • Wargo JA; 1] Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA. [2] Department of Genomic Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
  • Bivona TG; 1] Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
Nat Genet ; 47(3): 250-6, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25665005
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfoproteínas / Proteínas Serina-Treonina Quinases / MAP Quinase Quinase Quinases / Proteínas Proto-Oncogênicas B-raf / Proteínas Adaptadoras de Transdução de Sinal / Inibidores de Proteínas Quinases Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfoproteínas / Proteínas Serina-Treonina Quinases / MAP Quinase Quinase Quinases / Proteínas Proto-Oncogênicas B-raf / Proteínas Adaptadoras de Transdução de Sinal / Inibidores de Proteínas Quinases Idioma: En Ano de publicação: 2015 Tipo de documento: Article